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OBJECTIVES: To evaluate impact of TNF-alfa inhibitors reim-
bursement (adalimumab, etanercept and inﬂiximab) in the treat-
ment of ankylosing spondylitis (AS) on Polish National Heath
Fund’s budget. METHODS: Budget impact from the perspective
of public payer (National Heath Fund) in the 3 years time
horizon was constructed. The number of patients eligible for
treatment was estimated based on epidemiological data on AS
prevalence from other European countries and statement of
polish experts on minimal availability of biological treatment in
Poland (0.4% of AS patients). Costs analyzed: acquisition costs
of drugs, drug administration and treatment monitoring costs,
adverse events treatment costs including tuberculosis monitoring
and treatment costs, and AS hospitalization costs. Health out-
comes included quality-adjusted life-year (QALY) and were esti-
mated based on date from systematic review and economic
analysis. Multiple sensitivity and scenario analyses were per-
formed. Values are presented in PLN (exchange rate: 1
Euro = 3.40 PLN). RESULTS: In base scenario 184 AS patients
were eligible for TNF-alfa inhibitors treatment annually. Assum-
ing equal market share between adalimumab, etanercept and
inﬂiximab total one year treatment cost after market share
stabilization were calculated for 10.63 mln PLN and comprised
3.38 and 3.87 mln PLN for adalimumab, etanercept and
inﬂiximab-based treatments, respectively. Total 3-years treatment
costs assuming one year time to cover target population and
2-years time to reach market share stabilization was 27.72mln
PLN. Incremental annual cost while comparing base scenario
with worse scenario (all patients treated only with standard care
and no TNF-alfa inhibitors) ranged from 5.86 to 10.43 mln PLN.
Corresponding health beneﬁt represented annual increase in
QALY of 90 to 118 years. CONCLUSIONS: The impact of
TNF-alfa inhibitors on Polish National Heath Fund’s budget for
limited to less than 200 patients population is marginal.
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OBJECTIVES: Recent evidence has demonstrated a link between
disease severity in rheumatoid arthritis and overall non-drug
costs to the health care payer. This analysis aims to estimate
the likely lifetime cost savings associated with achieving better
clinical response in patients treated with etanercept, compared
against rituximab after the failure of two previous DMARD
therapies. METHODS: An existing economic model was repopu-
lated using data linking resource use with disease severity, as
measured by the Health Assessment Questionnaire (HAQ). The
model uses Markov techniques to predict the lifetime health
outcomes associated with different treatments for patients with
RA in the UK. For each treatment in the model, the initial (ﬁrst
six months), medium-term (six to thirty-six months) and long-
term (after thirty-six months) effects on the Health Assessment
Questionnaire (HAQ) score were calculated. HAQ scores at each
time period determined each patient’s utility (QALYs), resource
use and mortality. Effectiveness data were derived from the
results from the TEMPO trial and published literature. Utility
scores were converted from HAQ data using the EQ-5D. Unit
cost data were drawn from established national databases, and
were multiplied by resource use to predict the total cost for each
cohort. RESULTS: When the impact of HAQ on resource was
not included in the model, the incremental cost of the etanercept
arm was estimated to be £4648 over the patient’s lifetime. When
resource use was linked with response to treatment, the incre-
mental cost fell to £3304 (a reduction of 29%). Because the
incremental effectiveness of etanercept would remain unchanged,
the incremental cost-effectiveness ratio would also be reduced by
29%. CONCLUSIONS: By incorporating a link between HAQ
and resource use into an existing economic model, it has been
established that a substantial proportion of a treatment’s incre-
mental cost may be offset by reduced use of resources in other
areas.
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OBJECTIVES: Biological drugs, which are used for the treatment
of severe rheumatoid arthritis (RA), have high unit costs. This
has caused attention to the choice between the available biologi-
cal drugs at Danish hospitals. The ofﬁcial list unit costs can be
misleading if clinically indicated dose escalation or treatment
breaks affect the total consumption of the drug. The purpose of
this study was to compare the actual costs of treatment of RA
with the three most commonly used biological drugs (inﬂiximab,
etanercept and adalimumab) at Danish hospitals. METHODS:
The study is a cost-minimization analysis designed as a retrospec-
tive cohort study using data from medical records (n = 198).
Data was collected at three Danish hospitals. Consumption of
biological drugs was measured during a 12 months period.
Regression analysis was used to analyze the inﬂuence from
patient characteristics on the dosage of inﬂiximab. Breaks in the
treatment with etanercept and adalimumab were measured from
pharmacy records at one hospital. RESULTS: The average
annual costs of inﬂiximab vary due to dose escalation from
€10,546 at one hospital to €16,109 at another hospital. Regres-
sion analysis show that dose escalation of inﬂiximab is positively
associated with pain index (DAS28) and duration of therapy.
The average annual costs of etanercept and adalimumab were
€13,321 (both drugs) after adjustment for treatment breaks,
which accounted for 20% of the time at one hospital. CONCLU-
SIONS: Real-life medicine expenses for treatment of RA with
inﬂiximab, etanercept and adalimumab tend to be equal due to
dose escalation of inﬂiximab and treatment breaks with etaner-
cept and adalimumab. Consequently, the choice of drug can be
based on considerations of efﬁcacy, safety, patient needs and the
feasibility of the treatment.
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OBJECTIVES: To compare the cost-effectiveness ratios of etan-
ercept in ﬁrst line to etanercept in second line, together with
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methotrexate both in severe and highly active RA. METHODS:
A lifetime deterministic Markov model was developed compar-
ing two treatment sequences within two hypothetical cohorts of
patients. Five to six treatment sequences were considered in each
arm. Patients switched to the next sequence in case of lack of
effectiveness or in case of severe adverse events. Patients’ health
status was deﬁned by the Health Assessment Questionnaire
(HAQ), scale which demonstrated strong links with mortality
and quality of life. Scores were updated at every six-month model
cycles. Treatment failure occurred if the score did not improve by
0.35 point over the cycle. HAQ scores were converted into utility
coefﬁcients. Effectiveness data (HAQ progression, serious
adverse events and mortality) were derived from TEMPO trial
and literature. Only direct medical costs were considered.
Resource use was estimated through published data and expert
opinion. Costs were derived from French ofﬁcial sources. Sensi-
tivity analyses were performed on main model parameters.
RESULTS: The results showed that QALYs (Quality-Adjusted
Life-Years) were increased respectively in severe and highly active
RA by 0.98 (9.10vs8.12) and 0.73 (10.52vs9.78) in patients
treated with etanercept as 1st line compared with etanercept as
2nd line. The lifetime costs per patient were respectively in severe
and highly active RA €214,327 and €233,262 with etanercept as
1st line and €190,236 and €211,148 with etanercept as 2nd line
agent. Incremental cost-effectiveness ratios (ICER) were respec-
tively in severe and highly active RA: €24,655 and €30,199 per
QALY. Ratios ranged from €10,784 to €83,174 per QALY in
one-way sensitivity analyses. CONCLUSIONS: Treatment
sequence including etanercept as 1st line may be cost-effective in
the management of severe and highly active RA in France with
ICER fallen within acceptable range.
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OBJECTIVES: Poor compliance and failure to persist with drug
therapy are of potential economic signiﬁcance. The objective of
this study is to assess the impact of medication non-compliance
and non-persistence on economic evaluations in osteoporosis.
METHODS: A Markov microsimulation model with a lifetime
horizon and a societal perspective was used to analyse the impact
of non-adherence to biphosphonate therapy on costs (drug,
disease and total), on outcomes (Quality-Adjusted Life Years and
number of fractures saved) and on the cost-utility of biphospho-
nate therapy versus no treatment. Analyses were performed for
caucasian women aged 70 years with a diagnosis of osteoporosis
(t-score  -2.5). The relationship between compliance and frac-
ture efﬁcacy were taken from published sources and drug cost
was proportionate to compliance level. To model persistence to
therapy, we assumed that women can stop therapy after 3
months, 6 months, 1 year, 2 years or 3 years. RESULTS: Full
adherence to therapy resulted in a QALY gain of 0.0397, a 7.6%
reduction in the number of fractures and a higher cost of €383
compared to no treatment. Lower compliance was associated
with a decrease in QALY gain, a reduction in the number of
fractures saved and a higher disease cost compensated by a lower
drug cost. The cost per QALY gained for biphosphonate therapy
versus no treatment increased progressively with decreasing com-
pliance and was €9,653 €29,570 and €46,389 at 100%, 50% and
20% of compliance respectively. Realistic persistence assumption
(with full compliance) resulted in a lower QALY gain (only
0.0165) and a higher cost per QALY gained (€12,479). CON-
CLUSIONS: This study indicated that non-compliance and non-
persistence to osteoporotic therapy result not only in worsening
health outcomes, but also in a signiﬁcant change in cost-
effectiveness. Therefore, the effects of non-compliance and non-
persistence should be an integral part of economic evaluations in
osteoporosis.
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OBJECTIVES: New biologic therapies with distinct mechanisms
of action offer alternatives to rheumatologists and hope to
patients with moderate to severely active rheumatoid arthritis
(RA) and an inadequate response to anti-TNF therapy. The
objective of this study was to assess the cost-effectiveness of
abatacept and rituximab in biologic treatment sequences in
patients with RA and an inadequate response to one anti-TNF
agent. METHODS: An advanced simulation model was devel-
oped to assess the cost-effectiveness of two biologic strategies in
etanercept inadequate-responders: Strategy A—abatacept fol-
lowed by adalimumab (in case of an inadequate response to
abatacept); Strategy B—rituximab followed by adalimumab (in
case of an inadequate response to rituximab). Two clinically
relevant effectiveness endpoints were used: low disease activity
state (LDAS) (DAS28 3.2) and remission (DAS28 <2.6). Effec-
tiveness estimates for abatacept and rituximab were derived
from published pivotal trials and long-term extension studies,
assuming similar patient populations. Overall effectiveness was
expressed in theoretical expected number of days (TEND) under
remission or LDAS for each sequence after 2 years. French RA
direct medical costs were derived from a costing model based on
DAS28 categories. Using 4 ¥ 6-month cycles, drug costs were
estimated based on recommended dosing. Assuming a sustained
response over 6-month cycles, the rituximab re-treatment inter-
val was set at 6 months. Monte-Carlo simulations generated
mean values and standard deviations of costs, effectiveness and
mean cost-effectiveness over 2 years. Signiﬁcance tests were
performed to conﬁrm differences. RESULTS: Using the LDAS
endpoint, Strategy A (abatacept as second biologic agent) was
signiﬁcantly more efﬁcacious over 2 years versus (vs) Strategy B
(rituximab as second biologic agent), with 134 vs 107 TEND
under LDAS (p < 0.01). Mean cost-effectiveness ratios showed
signiﬁcantly lower overall medical costs per TEND under LDAS
with Strategy A vs Strategy B (€212 vs €234; p < 0.01). Using the
remission endpoint, Strategy A (abatacept as second biologic
agent) was signiﬁcantly more efﬁcacious over 2 years vs Strategy
B (rituximab as second biologic agent), with 61 vs 37 TEND
under remission (p < 0.01). Mean cost-effectiveness ratios
showed signiﬁcantly lower overall medical costs per TEND
under remission with Strategy A vs Strategy B (€446 vs €642;
p < 0.01). CONCLUSIONS: This innovative and robust model is
the ﬁrst to use LDAS and remission to compare biologic strate-
gies in France, aligned with RA treatment goals. The results
suggest that when used as the second biologic agent after an
inadequate response to one anti-TNF agent, abatacept appears
signiﬁcantly more efﬁcacious and cost-effective than ritux-
imab.This innovative and robust model is the ﬁrst to use LDAS
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